uniQure Q1 net loss $77.2M ($1.63/shr); cash $315.3M; on track for AMT-130 data Q2

uniQure N.V.

2023-Q1 EPS reported -$1.63 revenue$5,325,000

Revenue $5.3M (up from $1.8M YoY) on $4.9M contract manufacturing for HEMGENIX.
Eligible for $100M milestone from CSL on first US commercial sale of HEMGENIX; $75M European milestone by July 2, 2023.
Huntington's disease AMT-130: 1-2 year follow-up data from US Phase I/II expected Q2 2023; higher-dose enrollment in EU trial to complete mid-2023.
Pipeline advancing: AMT-162 (SOD1-ALS) Phase I/II start H2 2023; AMT-260 (epilepsy) and AMT-191 (Fabry) IND filings in 2023.
Cash $315.3M expected to fund operations into 2025 ($100M milestone assumed) or H1 2025 if $75M European milestone achieved.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

uniQure N.V. reported the first quarter of 2023 results: revenue $5.3 million.

Period: the first quarter of 2023
Revenue: $5.3 million
Result: reported results

Exact text from the filing

Revenue for the three months ended March 31, 2023 was $5.3 million, compared to $1.8 million in the same period in 2022.

View on SEC.gov

Browse all earnings releases →

uniQure N.V. filing history →

Source: SEC EDGAR

accession 0001104659-23-057516

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.